Final Results of the Prospective ADVATE® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII.

Published in: Journal of blood medicine (2021)

Data suggest that rAHF ITI therapy in the PAIR study was effective, with no unexpected safety signals reported.

Keyphrases